(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5...A, Md., Jan. 8 Northwest Biotherapeutics, Inc. (O..."Company" or "NWBT") announced today settlement of...e Northwest Biotherapeutics, Inc. Securities Lit...ed to pay in settlement US$1 million, which is to ...nt must be approved by the Court. Additional deta...
... ALTOS, Calif., Jan. 8 InteKrin Therapeutics, Inc... Healthcare Conference at,9:00 a.m. Pacific Time o...tin,St. Francis in San Francisco, California. Inte... will present at the conference. , About InteK...erapeutics is a privately-held clinical stage biop...
...BRIDGE, Mass., Jan. 8 /PRNewswire/ -- The Nano S...unced that the Nanotech Conference & Expo 2009...own Convention Center, in Houston, Texas. Now in ...technology event is expected to attract a communit...y executives, who will gather to promote advanced ...
Other Biology Technology:Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4...ia cardiac puncture from 3 to 4 week old rabbits (...ged and frozen at -70C. The complement is thawed, ...ored at -70C. DIRECT SALES FROM PEL-FREEZ BIOLOGIC... YOU CAN NOW BUY DIRECTLY FROM THE SOURCE! FORMER ...
Thermal Grayscale USB Printer for Imaging Systems; USB Connection from Alpha Innotech
GIBCO Newborn Calf Serum Heat-Inactivated from Invitrogen
Ready-To-Use IHC Bluing Reagent from Bethyl Laboratories
Biology Products: